FDA Grants Priority Review to Sanofi for Type 1 Diabetes in Young Children
Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2…